Loading clinical trials...
Loading clinical trials...
A Phase II-R and a Phase III Trial Evaluating Both Erlotinib (Ph II-R) and Chemoradiation (Ph III) as Adjuvant Treatment for Patients With Resected Head of Pancreas Adenocarcinoma
Conditions
Interventions
3-Dimensional Conformal Radiation Therapy
Biospecimen Collection
+10 more
Locations
689
United States
Providence Hospital
Mobile, Alabama, United States
Alaska Breast Care and Surgery LLC
Anchorage, Alaska, United States
Alaska Women's Cancer Care
Anchorage, Alaska, United States
Katmai Oncology Group
Anchorage, Alaska, United States
Providence Alaska Medical Center
Anchorage, Alaska, United States
Sutter Cancer Centers Radiation Oncology Services-Auburn
Auburn, California, United States
Start Date
April 5, 2010
Primary Completion Date
December 10, 2023
Completion Date
September 4, 2025
Last Updated
February 23, 2026
NCT02600949
NCT06921928
NCT06423326
NCT07542041
NCT04389632
NCT04895709
Lead Sponsor
National Cancer Institute (NCI)
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions